Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vascular Surgery

Free Subscription Articles published in Am Heart J Retrieve available abstracts of 67 articles: HTML format

Single Articles

October 2025
1. LEOSDOTTIR M, Dahlbom L, Back M, Wallentin L, et al
   Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy.
   Am Heart J. 2025;288:149-158.
   PubMed     Abstract available
   
   
   September 2025
2. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
   Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
   Am Heart J. 2025;287:94-106.
   PubMed     Abstract available
   
   
   June 2025
3. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
   Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
   Am Heart J. 2025;284:11-19.
   PubMed     Abstract available
   
   
   May 2025
4. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
   Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
   Am Heart J. 2025;283:26-36.
   PubMed     Abstract available
   
   
   April 2025
5. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
   Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
   Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
6. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
   Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
   Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
7. COSSETTE F, Trifan A, Prevost-Marcotte G, Doolub G, et al
   Tailored hydration for the prevention of contrast-induced acute kidney injury after coronary angiogram or PCI: A systematic review and meta-analysis.
   Am Heart J. 2025;282:93-102.
   PubMed     Abstract available
   
   
   March 2025
8. ROSOVSKY RP, Konstantinides SV, Moriarty JM, Dohad SY, et al
   A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatment of intermediate-high-risk acute pulmonary embolism: Rationale and design of the ST
   Am Heart J. 2025 Mar 31:S0002-8703(25)00100-0. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
9. HOFMANN R, James S, Sundqvist MO, Warme J, et al
   HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction(HELP-MI SWEDEHEART)Design and rationale of a cluster randomized, crossover, registry-based clinical trial.
   Am Heart J. 2025 Mar 27:S0002-8703(25)00096-1. doi: 10.1016/j.ahj.2025.
   PubMed     Abstract available
   
   
   
10. ZEYMER U, Hassinger F, Bramlage P, Schafer A, et al
    Hyperoxemic Oxygen Therapy in Patients with Acute Anterior Myocardial Infarction: HOT-AAMI - Design and Rationale of a Randomized Trial.
    Am Heart J. 2025 Mar 21:S0002-8703(25)00095-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
11. SISTA AK, Troxel AB, Tarpey T, Parpia S, et al
    Rationale and design of the PE-TRACT trial: A multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism.
    Am Heart J. 2025;281:112-122.
    PubMed     Abstract available
    
    
    February 2025
12. JACOBSEN MR, Jabbari R, Grove EL, Maeng M, et al
    Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT.
    Am Heart J. 2025 Feb 25:S0002-8703(25)00059-6. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
13. CHATUR S, Seth M, Casey M, Thompson M, et al
    Reminders EMbedded IN PCI Reports to Optimize Discharge Diabetes Mellitus Care (REMIND-DM): Rationale, Design, and Baseline Characteristics.
    Am Heart J. 2025 Feb 21:S0002-8703(25)00019-5. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
14. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
15. BAINEY KR, Welsh RC, Zheng Y, Arias-Mendoza A, et al
    Pharmaco-invasive Strategy and Dosing of Tenecteplase in STEMI Patients 60 to <75 Years: An Inter-trial Comparison of the STREAM-1 and STREAM-2 Trials: Comparison of Patients 60 to <75 Years in STREAM-1 and -2.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00032-8. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
16. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
17. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    January 2025
18. STEG PG, Nicolas J, Baber U, Sartori S, et al
    Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial.
    Am Heart J. 2025 Jan 29:S0002-8703(25)00016-X. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
19. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    PubMed     Abstract available
    
    
    
20. VELDTMAN GR, Abualsaud A, Cohen S, Ordonez MV, et al
    Fontan circulation and systemic disease - a retrospective cohort analysis over 35 years of follow-up.
    Am Heart J. 2025;279:40-49.
    PubMed     Abstract available
    
    
    
21. YAN S, Jiang F, Sun Y, Wang Y, et al
    Methylprednisolone for acute type A aortic dissection patients undergoing total arch replacement: Design and rationale of the Medal trial.
    Am Heart J. 2025;279:20-26.
    PubMed     Abstract available
    
    
    December 2024
22. CARULLI E, McGarvey M, Chabok M, Panoulas V, et al
    Transcoronary cooling and dilution for cardioprotection during revascularisation for ST-segment elevation myocardial infarction: design and rationale of the STEMI-Cool study.
    Am Heart J. 2024 Dec 30:S0002-8703(24)00338-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
23. XU L, Xu H, Wu S, Zhang H, et al
    Indobufen-based Dual Antiplatelet Therapy in Patients with Multivessel Coronary Disease Undergoing Drug-eluting Stent Implantation Insight From the OPTION Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00335-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
24. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
25. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
26. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    November 2024
27. FANAROFF AC, Vora AN, Wojdyla DM, Mehran R, et al
    Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS.
    Am Heart J. 2024 Nov 16:S0002-8703(24)00297-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
28. ABRAMOWITZ SD, Marko X, D'Souza D, Noor S, et al
    Rationale and Design of the DEFIANCE Study: A Randomized Controlled Trial of Mechanical Thrombectomy Versus Anticoagulation Alone for Iliofemoral Deep Vein Thrombosis.
    Am Heart J. 2024 Nov 2:S0002-8703(24)00278-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
29. ERLINGE D, Andersson J, Frobert O, Tornerud M, et al
    Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent.
    Am Heart J. 2024;277:1-10.
    PubMed     Abstract available
    
    
    October 2024
30. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
31. SAITO T, Kuno T, Fujisaki T, Gupta R, et al
    Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00266-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    September 2024
32. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    August 2024
33. VOGEL B, Jou S, Sartori S, Farhan S, et al
    Impact of sex on outcomes associated with polyvascular disease in patients after PCI.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00196-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
34. AIHARA K, Torii S, Nakamura N, Hozumi H, et al
    Pathological Evaluation of Predictors for Delayed Endothelial Coverage After Currently Available Drug-eluting Stent Implantation in Coronary Arteries: Impact of Lesions With Acute and Chronic Coronary Syndromes.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00197-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
35. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    July 2024
36. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
    Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
37. YANG Y, Chu TC, Suthar D, Beshish AG, et al
    Association of patient-level characteristics with long-term outcomes after Fontan palliation: Rationale, design, and baseline characteristics of the Pediatric Cardiac Care Consortium Fontan cohort study.
    Am Heart J. 2024;273:111-120.
    PubMed     Abstract available
    
    
    June 2024
38. JEYAPRAKASH P, Pathan F, Ozawa K, Robledo KP, et al
    Restoring microvascular circulation with diagnostic ultrasound and contrast agent: Rationale and Design of the REDUCE trial.
    Am Heart J. 2024 Jun 27:S0002-8703(24)00162-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
39. WU ZM, Kan J, Ye F, You W, et al
    PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
    Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
40. D'ENTREMONT MA, Lee SF, Mian R, Kedev S, et al
    Design and Rationale of the CLEAR SYNERGY (OASIS 9) Trial: A 2x2 Factorial Randomized Controlled Trial of Colchicine versus placebo and Spironolactone versus placebo in Patients with Myocardial Infarction.
    Am Heart J. 2024 Jun 25:S0002-8703(24)00161-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
41. SONG L, Guan C, Yu M, Sun Z, et al
    Sirolimus-eluting iron bioresorbable scaffold versus cobalt-chromium everolimus-eluting stents in patients with coronary artery disease: rationale and design of the IRONMAN-II trial.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00140-6. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
42. ZHANG RS, Maqsood MH, Greco AA, Postelnicu R, et al
    Efficacy and safety of catheter-based thrombectomy versus catheter-directed thrombolysis in acute pulmonary embolism.
    Am Heart J. 2024;272:109-112.
    PubMed     Abstract available
    
    
    May 2024
43. KIM Y, Park H, Yoon HJ, Suh J, et al
    Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
    Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
44. ZHANG F, Tian M, Wang X, Zhang H, et al
    Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
    Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
45. LEMLEY BA, Okunowo O, Ampah SB, Wu L, et al
    Effect of patient factors, center, and era on Fontan timing: An observational study using the Pediatric Health Information Systems Database.
    Am Heart J. 2024;271:156-163.
    PubMed     Abstract available
    
    
    April 2024
46. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
    Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
47. WEGERIF ECJ, Unlu C, Generaal MI, van den Bor R, et al
    Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual antiplatelet therapy (clopidogrel/acetylsalicylic acid) on the occurrence of atherothrombotic ev
    Am Heart J. 2024 Apr 10:S0002-8703(24)00080-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    March 2024
48. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
    Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
    Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    February 2024
49. MEHDIPOOR G, Redfors B, Chen S, Gkargkoulas F, et al
    Hypertension, Microvascular Obstruction and Infarct Size in Patients with STEMI Undergoing PCI: Pooled Analysis from 7 Cardiac Magnetic Resonance Imaging Studies.
    Am Heart J. 2024 Feb 29:S0002-8703(24)00050-4. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
50. LEE SH, Lee SJ, Heo JH, Ahn SG, et al
    Optimal antithrombotic strategy in patients with atrial fibrillation beyond 1 year after drug-eluting stent implantation: Design and rationale of the randomized ADAPT AF-DES trial.
    Am Heart J. 2024 Feb 22:S0002-8703(24)00041-3. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
51. DEHGHANI P, Singh J, Mancini GBJ, Stanberry L, et al
    Angiographic characteristics of Patients with STEMI and COVID-19 - Insights from NACMI Registry.
    Am Heart J. 2024 Feb 21:S0002-8703(24)00039-5. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
52. KEDHI E, Rroku A, Hermanides RS, Dambrink JH, et al
    TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary Bypass Grafting for Treatment of Patients with Aortic Valve Stenosis and M
    Am Heart J. 2024 Feb 1:S0002-8703(24)00019-X. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    January 2024
53. ASHWAT E, Brown JA, Yousef S, Ahmad D, et al
    Radial Artery versus Right Internal Mammary Artery as a Second Conduit during Coronary Artery Bypass Grafting.
    Am Heart J. 2024 Jan 20:S0002-8703(24)00015-2. doi: 10.1016/j.ahj.2024.
    PubMed     Abstract available
    
    
    
54. ALVIAR CL, Li BK, Keller NM, Bohula-May E, et al
    Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry.
    Am Heart J. 2024 Jan 6:S0002-8703(23)00361-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
55. ZHANG RS, Ho AM, Elbaum L, Greco AA, et al
    Quality and rapidity of anticoagulation in patients with acute pulmonary embolism undergoing mechanical thrombectomy.
    Am Heart J. 2024;267:91-94.
    PubMed     Abstract available
    
    
    December 2023
56. ABU-MUCH A, Grines CL, Batchelor WB, Maini AS, et al
    Influence of Left Ventricular Ejection Fraction in Patients Undergoing Contemporary pLVAD-Supported High-Risk PCI.
    Am Heart J. 2023 Dec 25:S0002-8703(23)00358-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
57. SIREN M, Leivo J, Anttonen E, Jolly SS, et al
    The Prognostic Significance of Single-Lead ST-Segment Resolution in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary PCI - A Substudy of the Randomized TOTAL Trial.
    Am Heart J. 2023 Dec 16:S0002-8703(23)00347-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
58. KANTHASAMY V, Schilling R, Zongo O, Khan K, et al
    Feasibility of Double-Blinded, Placebo-Controlled Interventional Study for Assessing Catheter Ablation Efficacy in Persistent Atrial Fibrillation: Insights from the ORBITA AF Feasibility study.
    Am Heart J. 2023 Dec 16:S0002-8703(23)00353-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
59. DILLEN DMM, Vlaar PJ, Vermeer AJE, Paradies V, et al
    Bifurcation PCI with a hybrid strategy with drug- eluting balloons versus a stepwise provisional two- stent strategy: Rationale and design of the hybrid DEB study.
    Am Heart J. 2023;266:168-175.
    PubMed     Abstract available
    
    
    November 2023
60. MUNHOZ D, Collet C, Mizukami T, Yong A, et al
    Rationale and design of the pullback pressure gradient (PPG) global registry.
    Am Heart J. 2023;265:170-179.
    PubMed     Abstract available
    
    
    October 2023
61. BAINEY KR, Wood DA, Bossard M, Campo G, et al
    Effects of Complete Revascularization According to Age in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease (COMPLETE-AGE).
    Am Heart J. 2023 Oct 21:S0002-8703(23)00297-1. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    September 2023
62. PUYMIRAT E, Soulat G, Fayol A, Mousseaux E, et al
    Rationale and Design of the Direct Oral Anticoagulants for Prevention of Left Ventricular Thrombus after Anterior Acute Myocardial Infarction (APERITIF) trial.
    Am Heart J. 2023 Sep 14:S0002-8703(23)00278-8. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
63. GONSALVES CF, Gibson CM, Stortecky S, Alvarez RA, et al
    Randomized Controlled Trial of Mechanical Thrombectomy Versus Catheter-directed Thrombolysis for Acute Hemodynamically Stable Pulmonary Embolism: Rationale and Design of the PEERLESS Study.
    Am Heart J. 2023 Sep 11:S0002-8703(23)00274-0. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    August 2023
64. PICCOLO R, Calabro P, Varricchio A, Baldi C, et al
    Rationale and Design of the PARTHENOPE Trial: A Two-by-Two Factorial Comparison of Polymer-Free vs. Biodegradable-Polymer Drug-Eluting Stents and Personalized vs. Standard Duration of Dual Antiplatelet Therapy in All-Comers Undergoing PCI.
    Am Heart J. 2023 Aug 10:S0002-8703(23)00188-6. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    July 2023
65. VAN DER SANGEN NMR, Kucuk IT, Sivanesan S, Appelman Y, et al
    Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients: Rationale and Design of the LEGACY study.
    Am Heart J. 2023 Jul 28:S0002-8703(23)00183-7. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    June 2023
66. BUJAK K, Vidal-Cales P, Gabani R, Rinaldi R, et al
    Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study.
    Am Heart J. 2023 Jun 4:S0002-8703(23)00141-2. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    
    
67. AHN JM, Kang DY, Lee PH, Ahn YK, et al
    Preventive PCI or Medical Therapy Alone for Vulnerable Atherosclerotic Coronary Plaque: Rationale and Design of the Randomized, Controlled PREVENT Trial.
    Am Heart J. 2023 Jun 2:S0002-8703(23)00134-5. doi: 10.1016/j.ahj.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vascular Surgery is free of charge.